Relevant bibliographies by topics / Non-sentinel lymph node

Academic literature on the topic 'Non-sentinel lymph node'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Non-sentinel lymph node.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Non-sentinel lymph node"

1

Picciotto, Franco, Gianluca Avallone, Federico Castellengo, Martina Merli, Virginia Caliendo, Rebecca Senetta, Adriana Lesca, et al. "Non-Sentinel Lymph Node Detection during Sentinel Lymph Node Biopsy in Not-Complete-Lymph-Node-Dissection Era: A New Technique for Better Staging and Treating Melanoma Patients." Journal of Clinical Medicine 10, no. 19 (September 23, 2021): 4319. http://dx.doi.org/10.3390/jcm10194319.

Full text
Abstract:
Sentinel lymph node biopsy has been demonstrated to be an effective staging procedure since its introduction in 1992. The new American Joint Committee on Cancer (AJCC) classification did not consider the lack of information that would result from the less usage of the complete lymph node dissection as for a diagnostic purpose. Thus, this makes it difficult the correct staging and would leave about 20% of the further positive non-sentinel lymph nodes in the lymph node basin. In this paper, we aim to describe a new surgical technique that, combined with single-photon emission computed tomography-computed tomography (SPECT-CT), allows for better staging of melanoma patients. This is a prospective study that includes 104 patients with cutaneous melanoma. Sentinel lymph node biopsy was offered according to the AJCC guideline. Planar lymphoscintigraphy was performed in association with SPECT-CT, identifying and removing all non-biologically “excluded” lymph nodes, guiding the surgeon’s hand in detection and removal of lymph nodes. Even if identification and removal of non-sentinel lymph nodes is unable to increase overall survival, it definitely gives better disease control in the basin. With a “classic” setting, the risk of leaving further lymph nodes out of the sentinel lymph node procedure is around 20%, thus, basically, the surgical sentinel lymph node of first and second lymph nodes would have therapeutic value and complete lymph node dissection classically performed.
APA, Harvard, Vancouver, ISO, and other styles
2

Oliveira, Andrea Fernandes de, Ivan Dunshee de Abranches Oliveira Santos, Thaís Cardoso de Mello Tucunduva, Luciana Garbelini Sanches, Renato Santos Oliveira Filho, Mílvia Maria Simões e. Silva Enokihara, and Lydia Masako Ferreira. "Sentinel lymph node biopsy in cutaneous melanoma." Acta Cirurgica Brasileira 22, no. 5 (October 2007): 332–36. http://dx.doi.org/10.1590/s0102-86502007000500002.

Full text
Abstract:
PURPOSE: To assess the importance of sentinel lymph node biopsy in patients with cutaneous melanoma. METHODS: Ninety consecutive non-randomized patients with stages I and II melanoma who underwent sentinel lymph node biopsy were followed up prospectively for six years. RESULTS: Patients were followed up for a mean period of 30 months. Their mean age was 53.3 years, ranging from 12 to 83 years. Thirty patients were male (37.5%) and 50, female (62.5%). Sentinel lymph node was positive in 32.5% and negative in 67.5%. It was found that the thicker the tumor, the greater the incidence of positive sentinel lymph nodes. In the group of patients with positive sentinel lymph nodes, recurrence occurred in 43.5%, but in those with negative sentinel lymph nodes, in only 7%, what points out to the association of tumor recurrence and positive sentinel lymph nodes. There were no major postoperative complications. CONCLUSION: Sentinel lymph node biopsy was demonstrated to be a safe method for selecting patients who need therapeutic lymphadenectomy.
APA, Harvard, Vancouver, ISO, and other styles
3

Santoro, Angela, Giuseppe Angelico, Frediano Inzani, Damiano Arciuolo, Saveria Spadola, Michele Valente, Nicoletta D’Alessandris, et al. "Standard ultrastaging compared to one-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastases in early stage cervical cancer." International Journal of Gynecologic Cancer 30, no. 12 (October 30, 2020): 1871–77. http://dx.doi.org/10.1136/ijgc-2020-001710.

Full text
Abstract:
ObjectiveWe compared ultrastaging and one-step nucleic acid amplification (OSNA) examination of sentinel lymph nodes in two homogeneous patient populations diagnosed with early stage cervical cancer. The primary aim of our study was to evaluate the rate and type of sentinel lymph node metastases detected by ultrastaging and OSNA assay. Secondary aims were to define the sensitivity and the negative predictive value of sentinel lymph node biopsy assessed with OSNA and ultrastaging and to define the role of sentinel lymph node assessment in predicting non-sentinel lymph node status.MethodsConsecutive patients who underwent surgery (radical hysterectomy or trachelectomy or cervical conization) at our institution, between January 2018 and March 2020, were enrolled. All patients had a preoperative diagnosis of early-stage cervical carcinoma (International Federation of Gynecology and Obstetrics (FIGO) 2018 stages IA–IIB) and underwent sentinel lymph node assessment with ultrastaging or OSNA. Patients with advanced FIGO stages and special histology subtypes (other than squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma) or patients with sentinel lymph nodes analyzed only with hematoxylin and eosin were excluded. Clinical data were compared using the χ2 test and Fisher’s exact test. A κ coefficient was determined with respect to lymph node assessment. A p value <0.05 was considered statistically significant.ResultsA total of 116 patients were included in this retrospective analysis (53 ultrastaging, 63 OSNA). Overall, 531 and 605 lymph nodes were removed in the ultrastaging and OSNA groups, respectively, and 140 and 129 sentinel lymph nodes were analyzed in the ultrastaging and OSNA groups, respectively. 22 patients had metastatic sentinel lymph nodes: 6 (11.3%) of 53 patients in the ultrastaging group and 16 (25.4%) of 63 patients in the OSNA group. The total amount of positive SLNs was 7 (5%) of 140 in the ultrastaging group and 21 (16.3%) of 129 in the OSNA group, respectively (p=0.0047). Pelvic lymphadenectomy was performed in 26 (49.1%) of 53 patients in the ultrastaging group and in 34 (54%) of 63 patients in the OSNA group due to comorbidities. Metastatic non-sentinel lymph nodes were found in 4 patients: 2 (7.7%) of 26 patients in the ultrastaging group and 2 (5.9%) of 34 patients in the OSNA group, respectively. The total amount of positive pelvic lymph nodes was 3 (0.6%) of 531 in the ultrastaging group and 4 (0.7%) of 605 in the OSNA group (p=0.61). In the OSNA group, only 2 patients with negative sentinel lymph nodes had metastatic disease in the pelvic lymph nodes. By contrast, no patients with OSNA-positive sentinel lymph nodes had metastases in the pelvic lymph nodes. In the ultrastaging group, all patients with negative sentinel lymph nodes did not have metastatic disease in other pelvic lymph nodes.ConclusionsOSNA assessment of sentinel lymph nodes was associated with a negative predictive value of 91% but poor reliability in detecting node metastases in non-sentinel pelvic lymph nodes. Of note, the ultrastaging protocol revealed higher sensitivity and more reliability in predicting pelvic non-sentinel lymph node status.
APA, Harvard, Vancouver, ISO, and other styles
4

Wong, Willard, Illana Rubenchik, Sharon Nofech-Mozes, Elzbieta Slodkowska, Carlos Parra-Herran, Wedad M. Hanna, and Fang-I. Lu. "Intraoperative Assessment of Sentinel Lymph Nodes in Breast Cancer Patients Post-Neoadjuvant Therapy." Technology in Cancer Research & Treatment 18 (January 1, 2019): 153303381882110. http://dx.doi.org/10.1177/1533033818821104.

Full text
Abstract:
Background: Shift toward minimizing axillary lymph node dissection in patients with breast cancer post neoadjuvant therapy has led to the assessment of sentinel lymph nodes by frozen section intraoperatively to determine the need for axillary lymph node dissection. However, few studies have examined the accuracy of sentinel lymph node frozen section after neoadjuvant therapy. Our objective is to compare the accuracy of sentinel lymph node frozen section in patients with breast cancer with and without neoadjuvant therapy and to identify features that may influence accuracy. Design: We identified 161 sentinel lymph node frozen section from 77 neoadjuvant therapy patients and 255 sentinel lymph node frozen section from 88 non-neoadjuvant therapy patients diagnosed between 2010 and 2016 in 2 institutions. The frozen section diagnoses were compared to the final diagnoses, and clinicopathologic data were analyzed. Results: The sensitivity, specificity, and accuracy of frozen section analysis were comparable between neoadjuvant therapy patients and non-neoadjuvant therapy patients (71.9% vs 50%, 100% vs 100%, and 88.3% vs 81.8%). Nine (11.7%) of 77 neoadjuvant therapy patients had discordant results, most often due to undersampling (tumor absent on frozen section slide). Four of these patients subsequently underwent axillary lymph node dissection. Discordant results (all false negatives) were significantly more likely in neoadjuvant therapy patients with Estrogen Receptor-positive/HER2-negative status, and in sentinel lymph node with pN1mic and pN0i+ deposits; age, preneoadjuvant therapy lymph node status, histotype, nuclear grade, tumor size, and response to neoadjuvant therapy showed no significant differences. For non-neoadjuvant therapy cases, large tumor size, lobular histotype, and sentinel lymph node with pN1mic and pN0i+ were associated with false-negative frozen section assessment. Conclusion: Sentinel lymph node frozen section diagnosis post-neoadjuvant therapy has comparable sensitivity, specificity, and accuracy to the sentinel lymph node frozen section diagnosis in the non-neoadjuvant therapy setting.
APA, Harvard, Vancouver, ISO, and other styles
5

Maguire, Aoife, and Edi Brogi. "Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift." Archives of Pathology & Laboratory Medicine 140, no. 8 (August 1, 2016): 791–98. http://dx.doi.org/10.5858/arpa.2015-0140-ra.

Full text
Abstract:
Context.—Sentinel lymph node biopsy has been established as the new standard of care for axillary staging in most patients with invasive breast carcinoma. Historically, all patients with a positive sentinel lymph node biopsy result underwent axillary lymph node dissection. Recent trials show that axillary lymph node dissection can be safely omitted in women with clinically node negative, T1 or T2 invasive breast cancer treated with breast-conserving surgery and whole-breast radiotherapy. This change in practice also has implications on the pathologic examination and reporting of sentinel lymph nodes.Objective.—To review recent clinical and pathologic studies of sentinel lymph nodes and explore how these findings influence the pathologic evaluation of sentinel lymph nodes.Data Sources.—Sources were published articles from peer-reviewed journals in PubMed (US National Library of Medicine) and published guidelines from the American Joint Committee on Cancer, the Union for International Cancer Control, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network.Conclusions.—The main goal of sentinel lymph node examination should be to detect all macrometastases (&gt;2 mm). Grossly sectioning sentinel lymph nodes at 2-mm intervals and evaluation of one hematoxylin-eosin–stained section from each block is the preferred method of pathologic evaluation. Axillary lymph node dissection can be safely omitted in clinically node-negative patients with negative sentinel lymph nodes, as well as in a selected group of patients with limited sentinel lymph node involvement. The pathologic features of the primary carcinoma and its sentinel lymph node metastases contribute to estimate the extent of non–sentinel lymph node involvement. This information is important to decide on further axillary treatment.
APA, Harvard, Vancouver, ISO, and other styles
6

Cecchi, Roberto, Cataldo De Gaudio, Lauro Buralli, and Stefania Innocenti. "Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Management of Primary Cutaneous Melanoma: Report of a Single-centre Experience." Tumori Journal 92, no. 2 (March 2006): 113–17. http://dx.doi.org/10.1177/030089160609200205.

Full text
Abstract:
Aims and Background Lymphatic mapping and sentinel lymph node biopsy provide important prognostic data in patients with early stage melanoma and are crucial in guiding the management of the tumor. We report our experience with lymphatic mapping and sentinel lymph node biopsy in a group of patients with primary cutaneous melanoma and discuss recent concepts and controversies on its use. Patients and Methods A total of 111 patients with stage I-II AJCC primary cutaneous melanoma underwent lymphatic mapping and sentinel lymph node biopsy from December 1999 through December 2004 using a standardized technique of preoperative lymphoscintigraphy and biopsy guided by blue dye injection in addition to a hand-held gamma probe. After removal, sentinel lymph nodes were submitted to serial sectioning and permanent preparations for histological and immunohistochemical examination. Complete lymph node dissection was performed only in patients with tumor-positive sentinel lymph nodes. Results Sentinel lymph nodes were identified and removed in all patients (detection rate of 100%), and metastases were found in 17 cases (15.3%). The incidence of metastasis in sentinel lymph nodes was 2.1%, 15.9%, 35.2%, and 41.6% for melanomas < or 1.0, 1.01-2.0, 2.01-4.0, and > 4.0 mm in thickness, respectively. Complete lymph node dissection was performed in 15 of 17 patients with positive sentinel lymph nodes, and metastases in non-sentinel lymph nodes were detected in only 2 cases (11.7%). Recurrences were more frequently observed in patients with a positive than in those with negative sentinel lymph node (41.1% vs 5.3% at a median follow-up of 31.5 months, P<0.001). The false-negative rate was 2.1%. Conclusions Our study confirms that lymphatic mapping and sentinel lymph node biopsy allow accurate staging and yield relevant prognostic information in patients with early stage melanoma.
APA, Harvard, Vancouver, ISO, and other styles
7

Coibion, Michel, Fabrice Olivier, Audrey Courtois, Nathalie Maes, Véronique Jossa, and Guy Jerusalem. "A Randomized Prospective Non-Inferiority Trial of Sentinel Lymph Node Biopsy in Early Breast Cancer: Blue Dye Compared with Indocyanine Green Fluorescence Tracer." Cancers 14, no. 4 (February 10, 2022): 888. http://dx.doi.org/10.3390/cancers14040888.

Full text
Abstract:
Background: Indocyanine green (ICG) is a promising tracer for sentinel lymph node biopsy in early breast cancer. This randomized study was conducted to evaluate sentinel lymph node biopsy with ICG compared with blue dye as a tracer in woman with early breast cancer without any sign of lymph node invasion. Methods: Between January 2019 and November 2020, 240 consecutive women with early breast cancer were enrolled and randomized to sentinel lymph node biopsy using ICG or blue dye. The primary endpoint was the sentinel lymph node detection rate in both arms. Results: ICG was used in 121 patients and detected sentinel lymph nodes in all patients (detection rate, 100%; 95% CI: 96.9–100.0) while blue dye was used in 119 patients and detected sentinel lymph nodes in 116 patients (detection rate: 97.5%, 95% CI: 92.9–99.1). This analysis indicated the non-inferiority of ICG vs. blue dye tracer (90%CI: −1.9–6.9; p = 0.0009). Conclusion: ICG represents a new promising tracer to detect sentinel lymph nodes in early breast cancer with a detection rate similar to other conventional tracers, and is associated with easy learning and low cost. Our result suggest that this technique is a good alternative to avoid radioactive isotope manipulation.
APA, Harvard, Vancouver, ISO, and other styles
8

Choi, Hee Jun, Jai Min Ryu, Byung Joo Chae, Seok Jin Nam, Jonghan Yu, Se Kyung Lee, Jeong Eon Lee, and Seok Won Kim. "Is Sentinel Lymph Node Biopsy for Breast Cancer with Cytology-Proven Axillary Metastasis Safe? A Prospective Single-Arm Study." Journal of Clinical Medicine 10, no. 20 (October 16, 2021): 4754. http://dx.doi.org/10.3390/jcm10204754.

Full text
Abstract:
The purpose of this study was to evaluate pathologic lymph node metastasis in breast cancer with cytology-proven axillary metastasis. This study was designed prospectively. We performed axillary lymph node dissections (ALND) after lymphatic mapping by near-infrared (NIR) fluorescence imaging with Indocyanine Green (ICG). We evaluated 72 breast cancer patients with cytology-proven axillary metastasis by curative surgery at the Samsung Medical Center between May of 2016 and December of 2017. Among the 72 patients with cytology-proven axillary metastasis, 14 of 39 patients (35.9%) with one or two sentinel lymph nodes containing metastases were metastasized to post-sentinel lymph node. Thirteen of fourteen patients had additional non-sentinel lymph node metastases, seven of thirteen patients also had additional level II lymph node metastases, and one patient had only one additional level II lymph node metastasis. Of T1 or T2 stage patients, 10 of 33 patients (30.3%) with one or two sentinel lymph nodes containing metastases were metastasized to post-sentinel lymph node. Even in patients without SLN metastasis, 50% of the patients had at least three LN metastases, and 40% in the T1 or T2 stage patients. Sentinel lymph node biopsy without ALND might be not safe for patients with cytology-proven axillary metastasis.
APA, Harvard, Vancouver, ISO, and other styles
9

Tominaga, Shusei. "Prediction of the non-sentinel node metastasis in patients without clinically axillary lymph node metastasis, with implication of breast cancer subtypes." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e13060-e13060. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13060.

Full text
Abstract:
e13060 Background: The accuracy of the nomogram about non-sentinel lymph node metastasis (NSLNM ) in breast cancer patients is still controversial to avoid axillary dissection particularly sentinel lymph node biopsy was positive. The aim of this study was to evaluate the necessity of adding breast cancer subtypes to the NSLNM nomgram variables. Methods: Between 2009 and 2011, consecutive breast cancer patients without clinically axillary lymph node metastasis (n=140) who received sentinel lymph node biopsy at Higashiosaka General Hospital were studied retrospectively. Twenty-two patients were turned out that breast cancer already spread to the sentinel nodes and all of 22 patients received complete axillary lymph node dissection. Results: Twelve patients had only sentinel lymph node metastases(Group S), 10 patients had non-SLN metastases (Group A). Patient characteristics and average probability of spread to additional lymph node developed by Memorial Sloan-Kettering Cancer Center (MSKCC) Nomogram were almost the same results in both groups. However, subtypes of Group S consisted of 8 HER2 positive , 2 triple negative, and 2 luminal A cases, subtypes of Group A consisted of 4 luminal A and 6 luminal B cases. Conclusions: Our data suggested that luminal type breast cancer tends to spread to non-sentinel lymph node metastasis and adding HER2, Ki-67, and intrinsic biological subtypes may improve predictivity of MSKCC nomogram.
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, Xuefei, Guochao Zhang, Zhichao Zuo, Qingli Zhu, Shafei Wu, Yidong Zhou, Feng Mao, et al. "Sentinel Lymph Node Positive Rate Predicts Non-Sentinel Lymph Node Metastasis in Breast Cancer." Journal of Surgical Research 271 (March 2022): 59–66. http://dx.doi.org/10.1016/j.jss.2021.09.039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Non-sentinel lymph node"

1

Elmadahm, Amira. "Analysis of clinical and pathological outcomes of sentinel lymph node biopsy in the SNAC Trial." Thesis, 2012. http://hdl.handle.net/2440/75703.

Full text
Abstract:
Sentinel Lymph Node Biopsy (SLNB) has become the standard procedure to assess the status of the lymphatic drainage in early stages of breast cancer. Currently, SLNB has replaced Complete Axillary Dissection (CAD) when the lymph nodes are clinically negative. The detection of a Sentinel Lymph Node (SLN) is critical for the success of SLNB procedure, but the accurate contribution of various clinical and pathological factors to the detection of SLNs has remained a controversial issue. This study, which is based on the database of a randomised controlled surgical trial of Sentinel Node biopsy versus Axillary Clearance (SNAC), is aimed at delineating the factors that can influence the outcomes of the SLNB and determining the clinical and pathological issues can predict the pathological outcomes of both SLNs and Non Sentinel Lymph Nodes (NSLN). Furthermore, a comparison of the ability of Cambridge nomogram, Stanford nomogram and Tenon score to predict the status of non sentinel lymph nodes was performed. Method: Retrospective analysis was made of all patient data involved in the SNAC trial in 2006:1088 patients were randomised into two groups: 544 patients allocated to the first group underwent sentinel lymph node biopsy followed by CAD; the second group 544 patients underwent SLNB followed by CAD if positive SLNs were identified. A combination of three techniques including preoperative lymphoscintigraphy (LSG), intraoperative blue dye injection and gamma probe in the operation theatre were used for mapping of the SLNs. Retrieved nodes were examined via Haematoxylin and Eosin and immunohistochemistry. Results: SLNs were identified in 1024 (94.6%) patients involved in the SNAC trial. Our analysis revealed that the highest Identification Rate (IR) was achieved by using the combination of three detection techniques: SLNs were detected in 96.3% (905 out of 940). The identification rates of preoperative LSG, intraoperative gamma probe and blue dye were 81.4%, 91.8% and 83% respectively. Patients‘ weights and the mode of primary tumour presentation have a significant impact on the overall outcomes of the sentinel lymph node detection. There were variations in the outcomes of multivariate analysis of factors influencing the detection of SLNs for each technique. The False Negative Rate (FNR), which was calculated only for patients who had SLNB followed by immediate CAD, was 8.3% and no significant correlation was found between various clinicopathological factors and the FNR. The involved SLNs were detected in 291 (28.4%) patients and involved non sentinel lymph nodes were identified in 118 out of 291 patients with positive SLNs. Regarding the prediction of the SLN status, the multivariate analysis models demonstrated that the size of the primary tumour (p = 0.000), the presence of Peritumoural Vascular Invasion (PVI) (p = 0.000), the primary tumour palpability (p = 0.036) and the site of the primary tumour (p = 0.038) were the most significant factors to predict the histopathological status of SLNs. The primary tumour size (p=0.015) and the diameter of the metastatic lesion (p=0.009) are the most significant predictors of the non sentinel lymph node status. Our validation of three nomograms to predict the positivity of NSLN revealed that the areas under the Receiver operating characteristics (ROC) curves were 0.697, 0.714 and 0.724 for Cambridge nomogram, Stanford nomogram and Tenon score respectively. Conclusion: the combined technique is superior to the single technique for SLN detection. The appropriate selection of patients to undergo SLNB procedure can minimise the failure of the sentinel lymph node detection. The presence of involved SLNs can be predicted from the primary tumour characteristics. The diameter of the primary tumour and the size of the metastatic lesion are independent predictors of NSLN involvement.
Thesis (M.S.) -- University of Adelaide, School of Medicine, 2012
APA, Harvard, Vancouver, ISO, and other styles
2

Murch, Lisa Elaine. "Evaluation of pathologic parameters and published nomograms in predicting non-sentinel lymph node metastases in female breast cancer patients with positive sentinel lymph nodes." 2007. http://hdl.handle.net/1993/21219.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Li, Jian. "Immunological parameters and small tumor deposits in sentinel and non-sentinel lymph nodes of breast cancer patients /." 2005. http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&doc_number=014952975&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Non-sentinel lymph node"

1

Branagan, Graham. Comparison between histological and molecular biological methods of detecting breast cancer metastases in sentinel and non-sentinel lymph nodes. Portsmouth: University of Portsmouth, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Amen Sibtain. Colorectal cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0015_update_001.

Full text
Abstract:
Breast cancer reviews the epidemiology and aetiology of this malignancy, with particular attention to the genetics underlying familial breast cancer, its pathology along with its receptors, oestrogen receptor (ER), the growth factor receptor HER2, and epidermal growth factor receptor (EGFR), and the bearing these have on treatment and prognosis. The benefits of breast cancer screening in the population and families at higher risk are discussed. Presenting symptoms and signs are followed by investigation including examination, bilateral mammography, and core biopsy of suspicious lesions. Management of non-invasive in situ disease is considered. Invasive breast cancer is staged according to TNM guidelines. Early breast cancer is defined, managed frequently by breast conserving surgery and sentinel node biopsy from the axilla. A positive sentinel node biopsy requires clearance of the axilla. Larger lesions may require mastectomy. Breast radiotherapy is indicated after breast conserving surgery. Following surgery, the risk of systemic micrometastatic disease is estimated from the primary size, lymph node spread, and tumour grade. Adjuvant chemotherapy improves treatment outcome in all but very good prognosis premenopausal breast cancer, and intermediate or poor prognosis postmenopausal breast cancer. This is combined with trastuzumab in HER2 positive disease. Adjuvant endocrine therapy is recommended for all ER positive breast cancer, tamoxifen in premenopausal, aromatase inhibitors in postmenopausal women. Neoadjuvant chemotherapy may be used in large operable breast cancers to facilitate breast conserving surgery. Locally advanced breast cancer is defined, its high risk of metastatic disease requiring full staging before treatment. Systemic therapy is often best first treatment, according to receptor profile. Metastatic breast cancer although incurable can be controlled for years using endocrine therapy, chemotherapy, trastuzumab, palliative radiotherapy, and bisphosphonates as appropriate. Male breast cancer is uncommon, but management similar.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Non-sentinel lymph node"

1

Kays, Joshua K., and Mark B. Faries. "Sentinel Lymph Node Mapping in Non-small Cell Lung, Colon, and Thyroid Carcinomas." In Cancer Metastasis Through the Lymphovascular System, 369–74. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-93084-4_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zarifmahmoudi, Leili, David N. Krag, Ramin Sadeghi, Reza Bagheri, and Susan Shafiee. "Radioguided Sentinel Lymph Node Mapping and Biopsy in Non-small Cell Lung Cancer (NSCLC)." In Radioguided Surgery, 315–33. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26051-8_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Boni, Giuseppe, Gianpiero Manca, Franca M. A. Melfi, Marco Lucchi, Alfredo Mussi, and Giuliano Mariani. "Radioguided Biopsy of the Sentinel Lymph Node in Patients with Non-Small Cell Lung Cancer." In Radioguided Surgery, 166–71. New York, NY: Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-38327-9_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wykes, James, Jonathan Clark, and Navin Niles. "The Role of Sentinel Lymph Node Biopsy in Non-melanoma Skin Cancer of the Head and Neck." In Head and Neck Cancer Clinics, 83–91. New Delhi: Springer India, 2015. http://dx.doi.org/10.1007/978-81-322-2497-6_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Champsas, Grigorios, and Othon Papadopoulos. "The Role of the Sentinel Lymph Node Biopsy in the Treatment of Nonmelanoma Skin Cancer and Cutaneous Melanoma." In Non-Melanoma Skin Cancer and Cutaneous Melanoma, 647–704. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-18797-2_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Non-sentinel lymph node"

1

Andrade, Danúbia Ariana de, Filomena Marino Carvalho, Fernando Nalesso Aguiar, Alfredo Luiz Jacomo, and Alfredo Carlos Simões Dornellas de Barros. "SIZE OF METASTATIC INFILTRATION IN THE SENTINEL NODE AS A PREDICTOR OF NON‑SENTINEL NODES INVOLVEMENT." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1065.

Full text
Abstract:
Introduction: The broad acceptance of sentinel lymph node biopsy (SLNB) led to an analysis for finding out the anatomopathological characteristics that can help predict the involvement of other axillary lymph nodes (LN) in positive sentinel lymph node (SLN) cases. Currently, it is very appropriate to investigate the cases that enable the omission of complete axillary dissection (CAD), even considering the involvement of the SLN. Some important studies on this theme were published, e.g., ACOSOG Z0011, and AMAROS. However, their results were not accepted uniformly enough because of methodological inconsistencies. Objectives: We aimed at providing a complementary basis for a pragmatic analysis of CAD after a positive SLNB in breast cancer. Methods: This is a cross-sectional study. Clinical and anatomopathological data were collected in patients with early-infiltrating breast cancer that were treated with SLNB, followed by CAD. Statistical analyses were performed using binary logistic regression and multiple logistic regression. Results: Out of 129 patients evaluated, compromise of non-sentinel additional lymph nodes was observed in 47 (36.4%) patients. According to an univariate analysis, the parameters related to non-SLN compromise were the tumor size in anatomopathological exam, histological grade III, the presence of peritumoral vascular embolism in focal area, compromise of more than one SLN, LN compromise rate of 100%, the presence of extracapsular neoplastic extension, perilymphnodal vascular involvement, perilymphatic fat compromise, and twenty or more dissected non-SNLs. The variables that increased the chance of compromise of non-SNL in the multivariate analysis were presented in following table with an accuracy of 81% (Figure). Conclusions: The tumor size on a clinical examination of the T2 category, the presence of two or more neoplastic foci in the SNL, and the size of the metastasis > 4.0 mm are the parameters that favor complete axillary lymphadenectomy.
APA, Harvard, Vancouver, ISO, and other styles
2

Reitsamer, R., S. Glueck, C. Menzel, and F. Peintinger. "Non-Sentinel Lymph Node Status of Patients with T1/T2 Breast Cancer and Micrometastasis in the Sentinel Lymph Node." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-1034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Huang, J., X. Chen, K. Shen, Y. Li, W. Chen, J. He, L. Zhu, et al. "Abstract P3-01-13: Risk factors of non-sentinel lymph node metastasis in breast cancer patients with metastatic sentinel lymph node." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p3-01-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gur, SA, B. Unal, R. Johnson, G. Ahrendt, M. Bonaventura, and A. Soran. "The predictive probability of four different breast cancer nomograms for non-sentinel axillary lymph node metastasis in positive sentinel lymph node biopsy." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tanaka, S., N. Sato, H. Fujioka, Y. Takahashi, K. Kimura, and M. Iwamoto. "P3-07-35: Validation of Online Calculators To Predict Non-Sentinel Lymph Node Status in Sentinel Lymph Node-Positive Breast Cancer Patients." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p3-07-35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dave, Rajiv V., Muhhamed N. Chauhan, Maria Ghaus, Sana Ahmed, Shiv Shapra, Joshua Marriott, Craig Sayers, Zbigniew Kryjak, and Deedar Ali. "Abstract P2-01-20: The ratio and size of positive sentinel lymph nodes predicts the involvement of non-sentinel lymph nodes following completion axillary lymph node dissection." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p2-01-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ballehaninna, UK, C. Andaz, and PI Borgen. "Abstract P1-01-10: Sentinel lymph node-II biopsy in breast cancer: A novel method to accurately predict non-sentinel axillary lymph node status." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p1-01-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Irakleidis, Foivos, Ashutosh Tondare, Hisham Hamed, and Ashutosh Kothari. "MANAGEMENT OF THE AXILLA IN PATIENTS WITH BREAST CANCER AND ONE OUT OF ONE POSITIVE SENTINEL LYMPH NODE. CAN WE OMIT AXILLARY LYMPH NODE CLEARANCE?" In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2063.

Full text
Abstract:
Background: Over the past three decades, the treatment of the axilla in breast cancer management continues to change. Current treatment strategies aim to achieve regional nodal control associated with reduced incidence of lymphedema and other long-term complications. In this study, we analyzed our tertiary center’s database of patients who had a single retrieved sentinel node (SN) that was positive for macrometastatic disease. We focused on AMAROS trial outcomes and the future view of treating this cohort of patients with axillary radiotherapy (RT) instead of axillary node clearance (ANC). Methods: Both the literature review and the 5-year retrospective analysis of our database were performed, focusing on the management of the axilla in patients with breast cancer with one-in-one positive SN. Results: A total of 24 patients who had surgery as primary treatment had one-in-one positive SN. All patients had the clinical and radiological assessment of their axilla prior to their sentinel lymph node biopsy (SNB). In all, 92% of these patients had a complete ANC, 50% of them had zero additional positive nodes, 21% had only one additional positive node, and a further 21% had more than one additional positive node. One patient was planned for ANC but died from chemotherapy-related complications and one more patient had alternative axillary RT instead of ANC. Of note, 80% of patients who had three or more positive axillary lymph nodes following ANC had indeed evidence of advanced locoregional disease and thus would not be eligible for alternative axillary RT, as compared with one patient who had a multifocal disease, could have axillary RT but had a heavy axillary burden on ANC. Finally, 71% of patients could have been offered alternative axillary RT but had ANC instead. Fourteen patients from this group had chest wall and supraclavicular fossa RT after their initial surgery, and thus, the addition of axillary RT instead of ANC could have been offered. Conclusion: In patients with early breast cancer and clinically node-negative axilla, disease burden in non-SN is limited and ANC may entail overtreatment. In view of low recurrence and complication rates seen in the AMAROS trial, axillary irradiation appears to be a valid and safe alternative when compared with ANC in patients with one-in-one positive SN.
APA, Harvard, Vancouver, ISO, and other styles
9

Nogi, H., K. Kawase, Y. Toriumi, H. Fukushima, M. Suzuki, and K. Uchida. "The Impact of CD44+CD24- Cells on Non-Sentinel Axillary Lymph Node Metastases in Sentinel Node-Positive Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-1160.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shigematsu, H., K. Taguchi, S. Shiotani, H. Kawaguchi, K. Nishiyama, S. Ohno, and M. Okada. "P3-07-27: ROCK II Expression Can Be a Potential Marker of Non-Sentinel Lymph Node Metastasis in Breast Cancer Patients with Sentinel Lymph Node Involvement." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p3-07-27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Non-sentinel lymph node' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography